Business Overview: Change Agents Corporation (NASDAQ: CHGA)

Executive Summary

Change Agents Corporation is the newly renamed identity (effective July 22, 2026) of Avalon GloboCare Corp., a Delaware-incorporated, Freehold, New Jersey-headquartered micro-cap that has cycled through several unrelated business models over the past five years — Chinese regenerative-cell therapy, a diagnostic laboratory joint venture, a terminated AI-automation merger with YOOV Group, and now a two-legged portfolio of (1) a consumer breath-ketone monitor, KetoAir, and (2) an early-stage "agentic AI" content and marketing-technology platform built around the December 2025 acquisition of RPM Interactive, Inc. (now Avalon Quantum AI, LLC). The company trades on Nasdaq under CHGA after a 1-for-20 reverse split (effective August 28, 2026) that it needed simply to regain the exchange's $1 minimum-bid-price requirement. With a market capitalization of roughly $2 million, an accumulated deficit of approximately $105.9 million, a 2025 net loss of $17.5 million, cash of only about $0.1 million, and an explicit "going concern" qualification from its auditors, CHGA is best understood not as a scaled operating business but as a capital-constrained micro-cap attempting a strategic pivot into AI software while a legacy consumer-health product generates de minimis revenue. It is a real, SEC-reporting operating company with its own 10-K (filed under the Avalon GloboCare name for fiscal 2025), so it clears the bar for individual analysis — but virtually every quantitative and qualitative signal points to a fragile, pre-revenue, high-dilution-risk story rather than a durable franchise.

1. Core Business Model & How They Work

CHGA operates as a holding company overseeing two structurally unrelated business lines rather than a single integrated operating model. The Consumer Health Technology segment distributes KetoAir, an FDA-registered (Class I), non-invasive breathalyzer that estimates nutritional ketosis by measuring breath acetone, under an exclusive North American distribution arrangement established in 2024. Revenue here is transactional — device and consumable sales through e-commerce and retail-adjacent channels — with no subscription or recurring-revenue architecture disclosed. The AI Content Technology segment, run through the wholly owned Avalon Quantum AI, LLC subsidiary, is being built as a SaaS model: two platforms, "Catch-Up" (an agentic short-form video generation tool for podcasters and creators, co-developed with AWS partner Caylent and beta-testing beginning September 2026) and "Beacon" (an AI Generative Engine Optimization tool targeted for a late-Q3 2026 launch, aimed at helping brands maintain visibility as consumers shift from Google-style search to AI assistants). Both AI products are pre-commercial; management has stated it does not expect meaningful RPM-platform revenue for roughly another year. In short, the "how they make money" answer today is: barely, and mostly from a low-margin consumer hardware/consumables line, while the company burns cash developing unproven software products it hopes will scale.

2. Business Segments

                         Change Agents Corporation (CHGA)
                                       |
        -------------------------------------------------------------
        |                                                            |
  Consumer Health Technology                          AI Content & Marketing Technology
  ("KetoAir")                                          (Avalon Quantum AI, LLC)
        |                                                            |
  - Non-invasive breath ketone monitor           - "Catch-Up": agentic AI short-form
  - FDA-registered Class I device                  video studio (beta Sept. 2026)
  - Exclusive N. American distribution           - "Beacon": AI Generative Engine
    agreement (2024– )                              Optimization tool (Q3 2026 launch)
  - THC breathalyzer discontinued                - Built via Dec. 2025 all-stock
    March 2026 (funding constraints)                acquisition of RPM Interactive
  - Early-stage, low revenue                     - Pre-revenue, beta stage

Neither segment is separately broken out with audited segment-level revenue and profit figures in publicly summarized disclosures, itself a signal of how immaterial current revenue is relative to corporate overhead and R&D spend.

3. Product Portfolio & Revenue Drivers

KetoAir is the company's only shipping, revenue-generating product: a hardware device plus (implicitly) recurring consumable/accessory purchases, competing in the diet/wellness quantified-self category. The AI portfolio consists of Catch-Up (autonomous, multi-platform short-form video generation for creators and podcasters, intended to be sold as a subscription SaaS tool) and Beacon (an "answer engine optimization" tool addressing the fast-growing need for brands to be surfaced correctly by ChatGPT-, Perplexity- and Gemini-style AI answer engines rather than classic blue-link search results). Management has also flagged, without committed contracts, an intent to explore AI software applications for defense, military and security customers — an unproven, aspirational revenue avenue disclosed but not yet monetized. None of these three product lines were reported as generating revenue sufficient to offset the company's cash burn; the 10-K explicitly frames both platforms as roughly a year away from meaningful commercialization. Historical revenue drivers — the wound-down China cell-therapy business and the 40%-owned Laboratory Services MSO stake (a roughly $20.7 million investment exited in February 2025 for just $1.745 million) — have both been abandoned, underscoring a pattern of capital destruction across successive pivots.

4. Competitive Landscape

In consumer ketone monitoring, KetoAir competes against inexpensive urine ketone test strips, blood ketone meters (e.g., Abbott's Precision Xtra) and other breath-based devices such as Keto-Mojo's breath/blood combination meters and the now largely discontinued Biosense breath acetone meter. The company's own risk disclosures concede that competitors carry "significantly greater financial resources, brand recognition, [and] established retail distribution networks" — a direct admission of sub-scale competitive positioning in a crowded, low-differentiation category. In AI-generated short-form video, Catch-Up would compete against well-funded, faster-moving players such as Synthesia, HeyGen, Runway, Pictory and OpusClip, as well as the video/creative tooling being pushed directly by hyperscalers and foundation-model labs (e.g., Google's Veo, OpenAI's Sora-based tools) — all of which have far larger training-data assets, cash reserves and engineering headcount than a two-employee microcap. In the emerging Generative Engine Optimization category that Beacon targets, competitors and adjacent incumbents include specialist entrants like Profound and Otterly.AI as well as legacy SEO platforms (Semrush, BrightEdge, Conductor) rapidly extending into AI-search visibility tooling — a category still being defined, meaning CHGA has no first-mover data or customer-base advantage despite entering early.

5. Strategic Strengths & Moats vs. Strategic Risks

Strengths: The company retains an FDA Class I registration for KetoAir (a modest regulatory credential, not a structural moat), a working relationship with an AWS Premier Tier partner (Caylent) that lends some technical credibility and possibly cost-subsidized development, and optionality from being an already-public Nasdaq shell that can pursue further stock-funded M&A (as it did with RPM Interactive) without a traditional IPO process.

Risks: These are severe and numerous. (1) Going concern: auditors have flagged substantial doubt about the company's ability to continue operating, with a working-capital deficit of roughly $12.7 million and only ~$0.1 million of cash. (2) Extreme dilution/volatility: the stock required a 1-for-20 reverse split in August 2026 after falling below Nasdaq's $1 minimum bid, and the 52-week range spans roughly $1.93 to $57.40 (split-adjusted), reflecting massive value destruction. (3) Strategy discontinuity: four distinct business identities (cell therapy → diagnostics JV → attempted YOOV merger → KetoAir/AI pivot) in roughly five years suggests opportunistic pivoting rather than durable competitive strategy. (4) Related-party governance concerns: the February 2026 sale of the company's Route 9 headquarters property to Chairman Wenzhao Lu for $9 million, with the company now leasing back the same facility from him, raises conflict-of-interest and capital-allocation questions. (5) Minimal organizational capacity: as of March 2026 the company had only two full-time employees plus contractors, an unusually thin base from which to compete against well-capitalized rivals in both consumer devices and AI software. (6) No demonstrated product-market fit for either AI platform, both of which are pre-revenue and beta-stage.

6. Financial Overview & Performance Matrix

The financial picture is unambiguous: this is a capital-starved company whose survival depends on near-term external financing (equity, debt, or further stock-funded transactions), not on internally generated cash flow from either its consumer device or its nascent AI platforms.

7. Summary Conclusion

Change Agents Corporation is a legitimate, SEC-reporting operating company with its own 10-K, but it is not a stable, analyzable "franchise" in the traditional equity-research sense — it is a distressed, serially-repositioning micro-cap now betting its remaining capital and credibility on two unproven AI software products (Catch-Up and Beacon) while a small legacy consumer-health device generates negligible revenue. Every hallmark of durable competitive advantage — brand, scale, switching costs, network effects, pricing power — is either absent or embryonic, and the going-concern qualification, thin cash position, extreme share-count compression, and repeated strategic pivots (culminating in a related-party real estate transaction with the chairman) all point to elevated execution and solvency risk. For a private equity-research library, CHGA is most useful as a case study in speculative micro-cap "AI-washing" and reverse-split dynamics rather than as a candidate for a constructive, moat-based long thesis.